Mitchell Steiner, Veru CEO

FDA ten­ta­tive­ly hints at EUA, with a tri­al re­quire­ment, for Veru's new Covid drug ahead of ad­comm

While ac­knowl­edg­ing that Veru’s po­ten­tial drug for Covid-19 hos­pi­tal­iza­tions hit the mark on mor­tal­i­ty in a small tri­al, and may have enough for an EUA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA